Skip to main content
Cardiosense Recieves FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure Read the press release

Press Releases

Cardiosense, Inc., Completes $15.1 Million Series A Financing to Advance AI Platform for Heart Disease

Keep reading